Here's why the Resonance Health (ASX:RHT) share price rocketed

The Resonance Health share price rocketed more than 16% today before closing 5% higher. We take a look at what's stirring investor interest.

| More on:
Young doctor raising arms in air with hands in fists celebrating a new development

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Resonance Health Ltd (ASX: RHT) share price rocketed more than 16% today before closing 5% higher.

The booming share price moves come after the company emerged from a trading halt late this morning. This follows the release of an announcement on its medical device.

What did Resonance Health report to send its shares higher?

In a late morning ASX release, Resonance Health announced that it has received Australian Therapeutic Goods Administration (TGA) approval for its HepaFat-AI device. The device provides fully automated artificial intelligence software to assesses liver fat.

With the TGA approval, Resonance Health can now supply its device across Australia. The company had already received clearance from the United States Food & Drug Administration (FDA) in early December.

HepaFat-AI automatically analyses magnetic resonance imaging (MRI) data. Subsequently, this data assesses liver fat in patients to give physicians a new tool in assessing patients with confirmed or suspected fatty liver disease.

According to Resonance Health, doctors can use the device to monitor patients for a number of issues. This will include patients in weight loss programs and screening the livers of live donors for transplant suitability. Additionally, the device will monitor patients who have or are believed to have non-alcoholic fatty liver disease (NAFLD) or the more serious subtype, non-alcoholic steatohepatitis (NASH).

Resonance Health reports that "NAFLD affects up to 2.3 billion people, a figure expected to grow year-on-year. Of these, about 470 million people (or 20%) will develop NASH". NASH can lead to serious health consequences, including liver failure.

The company plans to market the device to radiologists and physicians involved in the routine clinical diagnosis and management of patients with confirmed or suspected fatty liver disease. However, it also sees a market with pharmaceutical companies engaged in NASH drug development.

Resonance Health says its work in machine learning to develop assistance tools for the medical sector is continuing.

Share price snapshot

Over the past 12 months, Resonance Health shares are up 2.5%. That compares to a 1% loss on the All Ordinaries Index (ASX: XAO).

Year-to-date, the Resonance Health share price is down 10.8%.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Resonance Health Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Broker looking at the share price.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why ARB, Block, Mayne Pharma, and Paladin Energy shares are charging higher today

These shares are having a strong finish to the week. But why?

Read more »

A woman puts her hands up as she smashes and breaks through a glass ceiling.
Share Gainers

How these 5 ASX 200 stocks are smashing the benchmark this week

These fives ASX 200 stocks have made some very happy shareholders this week. Here’s how.

Read more »

Bored man sitting at his desk with his laptop.
Share Fallers

Why Catalyst Metals, Duratec, Nufarm, and Rio Tinto shares are dropping today

These shares are ending the week in the red. But why?

Read more »

A smiling woman at a hardware shop selects paint colours from a wall display.
Broker Notes

After its strategy day, what does Macquarie think Wesfarmers shares are worth?

Let's see what the broker is saying about this blue chip.

Read more »

Buy, hold, and sell ratings written on signs on a wooden pole.
Technology Shares

After surging 13% yesterday, are TechnologyOne shares a buy, hold or sell according to Macquarie?

Valuations matter when investing, and Macquarie feels no different.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Broker Notes

Broker reveals which ASX stocks are rate-cut winners

Macquarie is tipping three further interest rate cuts in July, August, and November.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Broker Notes

Where to invest $1,000 into ASX 200 shares in June

Goldman Sachs is tipping these shares as buys. Let's find out why.

Read more »